What Is PKAN Disease? Causes, Symptoms, and Diagnosis

Pantothenate kinase-associated neurodegeneration, or PKAN, is a rare inherited disorder in which iron builds up in specific regions of the brain, progressively damaging the nerve cells that control movement. It belongs to a family of conditions called neurodegeneration with brain iron accumulation (NBIA), and it is the most common subtype within that group. PKAN is caused by mutations in the PANK2 gene, which disrupts how the body makes a molecule essential to energy metabolism in cells. The disease typically emerges in childhood with worsening movement problems, though a significant minority of patients develop symptoms much later in life.

The Genetic Cause

PKAN follows an autosomal recessive inheritance pattern, meaning a child must inherit a faulty copy of the PANK2 gene from each parent to develop the disease.¹ Parents who each carry one mutated copy typically have no symptoms themselves. The PANK2 gene provides instructions for making a mitochondrial form of the enzyme pantothenate kinase, which plays a key role in synthesizing coenzyme A (CoA), a molecule involved in hundreds of metabolic reactions throughout the body.² When both copies of the gene are mutated, the enzyme either works poorly or not at all, and CoA levels in the brain drop.

Over 100 different PANK2 mutations have been identified. Some are point mutations that swap a single building block in the protein, while others involve larger deletions of gene segments. Research has found that some of these deletions may be triggered by repetitive DNA sequences flanking the gene that promote faulty recombination during cell division.³ The type and severity of the mutations matter: patients who carry two mutations that completely knock out the protein’s function tend to develop symptoms earlier in life, while those with at least one mutation that leaves some residual enzyme activity are more likely to have later onset.¹

Why Iron Accumulates in the Brain

The connection between a CoA shortage and iron buildup is not immediately obvious, and researchers have spent years working out the chain of events. CoA is essential for the function of mitochondria, the energy-producing structures inside cells. When CoA runs low, mitochondria malfunction, producing excess reactive oxygen species and disrupting the handling of iron within cells. Animal models of PKAN have shown that this CoA deficiency leads to abnormal iron metabolism, dopamine pathway changes, and impaired mitochondrial enzyme activity, all of which can be traced back to the breakdown of a downstream molecule called mitochondrial acyl carrier protein, which depends on CoA for its activation.⁴

The iron deposits concentrate heavily in a brain region called the globus pallidus, a structure deeply involved in coordinating voluntary movement. Neuropathological studies of confirmed PKAN cases have found not only iron deposits but also distinctive swollen nerve fibers called spheroid bodies and widespread protein aggregates tagged with ubiquitin, a molecular marker that cells use to flag damaged proteins for disposal.⁵ Together, iron toxicity, oxidative stress, and the accumulation of damaged proteins steadily destroy neurons in this region, producing the movement symptoms that define the disease.

Classic Versus Atypical Symptoms

PKAN exists on a clinical spectrum, but clinicians generally divide patients into two broad categories based on when symptoms appear and how quickly the disease progresses. These categories have real implications for daily life, care planning, and the kinds of symptoms that dominate the picture.

Classic PKAN accounts for the majority of cases. Symptoms usually begin before age six, and the hallmark is dystonia: involuntary muscle contractions that twist the body into abnormal postures. In young children this often first affects the legs, leading to an unusual gait or frequent falls. Over the following years, dystonia tends to spread to other body regions, and many patients develop difficulty speaking and swallowing. Walking ability is frequently lost within the first several years after symptom onset.

Atypical PKAN makes up roughly a quarter of cases. It tends to appear in the teens or twenties, though onset as late as the fifties has been documented. One reported case involved a 50-year-old woman whose first symptoms were progressive slurring and difficulty swallowing due to dystonia of the mouth and tongue; over time she developed involuntary eye-closing spasms, neck dystonia, parkinsonian features, and cognitive decline.⁶ Speech problems are often the first clue in atypical PKAN. Roughly a quarter of all PKAN patients present with speech difficulties such as stuttering, repetitive speech patterns, or slurring, along with delayed motor symptoms like slowed movement, rigidity, and freezing of gait.⁷ These features can easily be mistaken for Parkinson’s disease or other movement disorders, which is a real source of diagnostic delay.

Psychiatric and cognitive symptoms add another layer. Patients with atypical PKAN may develop obsessive thoughts, impulsive behavior, disinhibition, and executive function problems, sometimes well before the movement disorder becomes severe.⁸ Survey data from patients and caregivers support the idea that the two forms differ not just in age of onset but in the overall pattern and pace of decline.⁹

Eye Involvement

PKAN can affect the retina, the light-sensitive tissue at the back of the eye. In a study that examined patients with confirmed PANK2 mutations, only about four out of ten had visible pigmentary changes in the retina, but the majority had abnormal electrical responses when their retinas were tested, ranging from mild cone cell dysfunction to severe rod-cone impairment.¹⁰ This means the retina can be quietly deteriorating before a standard eye exam picks up any visible abnormality. Animal research in mice lacking the Pank2 gene has confirmed that photoreceptor cells thin progressively over time, consistent with a slow degenerative process driven by the same CoA deficiency that damages the brain.¹¹ Because of this, experts typically recommend regular eye monitoring, including specialized electrical testing, for anyone diagnosed with PKAN.

Diagnosis and the Eye-of-the-Tiger Sign

The single most recognizable diagnostic clue in PKAN is a brain MRI pattern known as the “eye of the tiger.” On certain MRI sequences, the globus pallidus appears dark due to heavy iron deposits, but a bright spot in the center, caused by tissue damage and scarring, creates a pattern that resembles a tiger’s eye.¹² When a young patient presents with progressive dystonia and this MRI pattern appears, clinicians have strong grounds to suspect PKAN.

That said, the eye-of-the-tiger sign has limits. It is highly suggestive of PKAN, but it has occasionally been reported in other conditions.¹³ And in atypical or very early cases, the sign may not be present on the first MRI. In at least one documented case, the pattern only became visible on a follow-up scan four years after symptoms began.⁶ This means a negative MRI early in the disease does not rule PKAN out.

Genetic testing for PANK2 mutations is the definitive confirmation. The process generally involves whole-exome sequencing or targeted gene panels. One challenge is that PKAN can initially resemble other conditions entirely. In a recent series of newly confirmed PKAN cases, one patient’s early symptoms looked like a mitochondrial disorder, while another initially resembled a different type of NBIA.¹⁴ The diagnostic journey for PKAN families can be long: a survey of caregivers found that many experienced years of uncertainty and visits to multiple specialists before receiving a definitive molecular diagnosis.¹⁵

Disease Progression and What to Expect

The trajectory of PKAN varies, but a prospective study of patients with atypical PKAN identified a recognizable pattern. Most patients in this cohort first developed dystonia around the mouth and jaw, followed within the first five years by generalized dystonia, speech and swallowing difficulties, balance problems, and dependence on others for daily activities. After that initial period of rapid decline, many patients entered a longer phase of slower progression, with complications like skeletal deformities emerging later.¹⁶ The average disease duration in that group was nearly 19 years.

Classic PKAN tends to progress more quickly. Children with early-onset disease often lose the ability to walk independently within a few years and frequently require a wheelchair before reaching their teens. Swallowing difficulties may eventually necessitate a feeding tube. The disease is life-shortening, though survival into adulthood is common, particularly with attentive supportive care.

The burden on caregivers is substantial. In one survey, over half of caregivers reported having to change their employment because of caregiving responsibilities, and the proportion of patients requiring full-time care rose steadily with disease severity, reaching 100 percent in the most severely affected group.¹⁵

Current Treatment Options

There is no established cure for PKAN, and treatment is currently focused on managing symptoms and slowing damage where possible.¹⁷ The most debilitating symptom for many patients is dystonia, and two approaches have shown the most promise in managing it. Baclofen, a muscle relaxant, can be delivered directly into the spinal fluid via an implanted pump (intrathecal baclofen), which helps reduce muscle spasms with fewer systemic side effects than oral medications. Botulinum toxin injections into specific muscles can also help when dystonia is concentrated in a particular body region, such as the jaw or neck.

Deferiprone, an iron-removing drug, is the most studied PKAN-specific therapy. A pilot trial found that it reduced iron load in the globus pallidus on MRI in all treated patients, and four patients showed clinical improvement within the first year.¹⁸ A larger controlled trial told a more nuanced story. After 18 months, patients taking deferiprone showed less worsening on a clinical disability scale compared to the placebo group, but the difference was not statistically significant. An encouraging finding came from the extension phase: patients who initially received placebo and then switched to deferiprone appeared to experience a slowing of progression, with disease worsening dropping from roughly 4.4 points over the first 18 months to 1.4 points over the next 18 months.¹⁹ However, patients themselves did not perceive a change in their condition when asked. Case reports suggest that combining deferiprone with intrathecal baclofen may offer more benefit than either therapy alone.²⁰

Deep brain stimulation (DBS) is another option considered in some centers. By delivering electrical pulses to specific brain targets, DBS can reduce dystonia in some patients, though the evidence base for its use in PKAN specifically is limited to case series and small studies, and responses can be variable.

Experimental Therapies Targeting the Root Cause

Because current treatments address downstream consequences rather than the core metabolic defect, researchers have been working on approaches that aim to restore CoA levels in the brain. This is genuinely difficult. The blood-brain barrier blocks many large molecules from entering the brain, which means simply giving CoA or its precursors by mouth may not get enough of the active compound into the neurons that need it most.

One promising strategy involves a compound called PZ-2891, designed specifically to cross the blood-brain barrier. Rather than supplying CoA directly, it works as an activator of the pantothenate kinase enzymes that are still functional in PKAN patients, specifically PANK1 and PANK3, the family members unaffected by the PANK2 mutation. In a severe PKAN mouse model, oral dosing with PZ-2891 raised brain CoA levels and substantially improved movement, growth, and survival.²¹ This remains preclinical work, but the concept of boosting alternate PANK enzymes to compensate for the broken one represents one of the most logical therapeutic angles being pursued.

Another approach has focused on a CoA pathway intermediate called 4′-phosphopantetheine. In mouse and cell models, feeding this compound normalized CoA levels, corrected iron and dopamine abnormalities, and restored mitochondrial enzyme function.⁴ Separately, direct supplementation of CoA itself has been shown to prevent cell death and reduce oxidative stress in human neurons derived from patients with PANK2 mutations.²² An earlier PKAN candidate drug, fosmetpantotenate, was designed to deliver a CoA precursor to the brain but failed in clinical trials, likely because its chemical properties made it poorly suited to cross the blood-brain barrier, a limitation that subsequent drug designs have tried to overcome.²¹

Tracking Disease With Blood Biomarkers

One of the persistent challenges in managing PKAN is measuring how the disease is progressing between clinic visits. Clinical rating scales depend on what a doctor observes or what a patient can perform on a given day, which introduces variability. Researchers have been looking for blood-based molecules that could offer a more objective window into what is happening in the brain.

Recent work has identified neurofilament light chain (NfL) as a key blood biomarker for PKAN patients. NfL is a structural protein released from nerve fibers when they are damaged, and higher levels in the blood reflect greater ongoing injury in the brain. Alongside NfL, two other proteins, UCH-L1 and tau, appear useful for monitoring disease progression in PKAN specifically.²³ These biomarkers are not yet part of routine clinical practice, but they could eventually help clinicians detect worsening earlier and evaluate whether a treatment is having a biological effect even before clinical changes become apparent.

Why the Disease Was Renamed

If you encounter older medical literature, you may see PKAN referred to as Hallervorden-Spatz disease, after the two German neuropathologists who first described the pattern of brain iron accumulation in 1922. The medical community moved away from this name in the early 2000s, and the reason goes beyond molecular taxonomy. Julius Hallervorden, one of the two namesakes, was actively involved in the Nazi euthanasia program during World War II, obtaining brain specimens from victims killed under the regime’s systematic murder of disabled people.²⁴ The renaming was both ethically motivated and scientifically convenient: the discovery of the PANK2 gene in 2001 gave clinicians a precise molecular label that accurately described the underlying cause. The transition from the old eponym to the new name accelerated through the 2000s and is now standard in the field.²⁵

PKAN Within the Broader NBIA Family

PKAN is the most common subtype of NBIA, but it is not the only one. At least eleven NBIA subtypes have now been described, each caused by a different gene mutation but all sharing the core feature of abnormal iron deposition in the brain.²⁶ PANK2 mutations account for the largest share.²⁷ The other relatively common subtypes include PLA2G6-associated neurodegeneration (PLAN), mitochondrial membrane protein-associated neurodegeneration (MPAN), and beta-propeller protein-associated neurodegeneration (BPAN). Each has distinctive clinical features, different rates of progression, and its own genetic test. The distinction matters because treatments being developed for PKAN target the CoA pathway specifically and would not be expected to help patients with other NBIA subtypes. Getting the precise molecular diagnosis, not just a general NBIA label, is critical for connecting patients to the right clinical trials and support communities.

Animal Models and Why They Matter for Patients

Much of what we know about PKAN’s biology comes from animal models, particularly fruit flies and mice engineered to lack the equivalent of the PANK2 gene. The Drosophila (fruit fly) model was among the first to demonstrate that pantothenate kinase deficiency leads to reduced CoA levels, mitochondrial dysfunction, and increased protein damage from oxidative stress.²⁸ A refined fly model allowed researchers to monitor neurodegeneration continuously in living animals, offering a real-time window into how the disease unfolds.²⁹

Mouse models have been trickier. Simply deleting the mouse version of PANK2 does not produce a severe brain phenotype, because mice rely more heavily on another family member, PANK1, to maintain brain CoA. Researchers solved this by creating a double-knockout model that removes both PANK1 and PANK2 in neurons, which produces the severe CoA deficiency, movement problems, and shortened lifespan seen in human PKAN.³⁰ This model has become the primary testing ground for experimental therapies. It is worth noting that the fly model led directly to the discovery that pantethine, a supplement available over the counter, could rescue CoA levels and brain degeneration in that species.²⁸ Whether pantethine has a meaningful effect in humans remains unclear, and no controlled human trials have confirmed a benefit, but the result illustrates how these models serve as screening tools for potential therapies.